Humulin I Kwikpen (Isophane) (Insulin Human)

Humulin I Kwikpen (Isophane) is indicated for the treatment of diabetes mellitus where basal insulin support is required.

• Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when oral agents or other injectables do not achieve glycemic targets.
• Adjunct therapy during pregnancy or lactation when a physician determines benefits outweigh risks.
• Use in patients transitioning from vials or other insulin delivery devices to a pen‑based system.
• Management of fasting hyperglycemia in combination with rapid‑acting insulin.

• Humulin I Kwikpen contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and stimulating glycogen synthesis. In the liver, it suppresses gluconeogenesis, thereby lowering circulating glucose levels and improves overall metabolic control.

Adverse reactions to Humulin I Kwikpen may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or loss of subcutaneous fat.
• Weight gain associated with improved glycemic control.
• Nausea or abdominal discomfort.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Edema or heart failure exacerbation in susceptible individuals.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Hypersensitivity leading to serum sickness‑like reaction.

When prescribing or using Humulin I Kwikpen, clinicians and patients should consider several safety precautions.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose regularly to avoid hypoglycemia, especially during dose changes.
• Adjust doses in patients with fluctuating dietary intake, exercise, or illness.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Store the pen at controlled room temperature and discard after the indicated in‑use period.
• Avoid using the pen after the solution becomes cloudy or discolored.
• Educate patients on proper injection technique to reduce lipodystrophy.

Humulin I Kwikpen can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.
• High‑dose corticosteroids that markedly increase blood glucose.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia.
• Diuretics, especially thiazides, which can raise glucose levels.
• ACE inhibitors or ARBs, as they may enhance insulin sensitivity.
• Alcohol consumption, which can cause delayed hypoglycemia.